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ABSTRACT 
Currently a marked interest in developing lipid-based formulations to deliver lipophilic compounds. Self-emulsifying system has emerged as a 
dynamic strategy for delivering poorly water-soluble compounds. These systems can embrace a wide variety of oils, surfactants, and co-solvents. An 
immediate fine emulsion is obtained on exposure to water/gastro-intestinal fluids. The principal interest is to develop a robust formula for 
biopharmaceutical challenging drug molecules. Starting with a brief classification system, this review signifies diverse mechanisms concerning lipid-
based excipients besides their role in influencing bioavailability, furthermore pertaining to their structured formulation aspects. Consecutive steps 
are vital in developing lipid-based systems for biopharmaceutical challenging actives. Such a crucial structured development is critical for achieving 
an optimum formula. Hence lipid excipients are initially scrutinized for their solubility and phase behavior, along with biological effects. Blends are 
screened by means of simple dilution test and are consequently studied with more advanced biopharmaceutical tests. After discerning of the 
principle formula, diverse technologies are offered to incorporate the fill-mass either in soft/hard gelatin capsules. There is also feasibility to 
formulated lipid-system as a solid dosage form. Although such solid technologies are desirable but such should not undermine the 
biopharmaceutical potential of lipid-formulations.  
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With today’s contemporary drug discovery techniques, innovating 
drug candidates without compromising on safety and efficacy is a 
challenge. Though there has been a remarkable success in the 
development of new drug candidates, there are still unmet needs in 
healthcare which need effective therapy [1]. Predominantly new 
chemical entities (NCE) (about 40%) with potential therapeutic 
activity and other pharmacokinetic aspects are compromised as a 
result of poor solubility, concerns with permeability, rapid metabolism 
and early elimination. Therefore, the pharmaceutical drug discovery 
phase for an NCE with appropriate biopharmaceutical properties is 
crucial for the successful development of the new drug.  
Hence the significance of pharmaceutical technology emerged to 
formulate bio pharmaceutically competent drugs. Several strategies 
exist to deal with drug molecules with lipophilicity or permeability 
includes micronization of crystalline solids, amorphous formulation, 
and lipid-based formulations. Lipid-based formulations, especially 
self-emulsifying formulations; self-micro emulsifying drug delivery 
system or self-nano emulsifying drug delivery system (SMEDDS or 
SNEDDS) prominently gained great significance as a successful 
approach for poorly soluble drugs amid other approaches [2-4]. 
Liposomes, lipoplexes, solid-lipid nanoparticle (SLN), SMEDDS, 
microemulsion, and macroemulsions mostly contribute to lipid-
based formulations. In recent years, lipid-based formulation attained 
importance with significant emphasis on self-emulsifying drug 
delivery system (SEDDS) [5]. Lipid-based formulations, especially 
SEDDS are emulsions with characteristically fine globule size and 
possess greater thermodynamic stability [6-8]. 
In gastrointestinal tract (GIT) upon mild agitation or gastrointestinal 
motility, SEDDS composed of isotropic mixtures of oils, surfactants, 
and co-solvents produce rapid fine emulsions [9, 10]. SEDDS 
effectively produce emulsions with a droplet size range of 100-200 nm 
for SMEDDS whereas SNEDDS produce less than 100 nm.  
It's significant to note that approach for producing fine emulsion by 
SMEDDS/SNEDDS is analogous to low-energy emulsification technique 
for nanoemulsions. The concentration of the surfactants and co-
surfactant within SMEDDS system influence diffusion of the drug from 
oil globule to dissolution media, therefore, diffusion fundamentally 
limits the rate of dissolution [11, 12]. The major difference between 
SEDDS, SMEDDS, and SNEDDS are listed in (table 1). 
 
Table 1: Major difference between SEDDS, SMEDDS, and SNEDDS 
Property SEDDS SMEDDS SNEDDS 
Size >300 nm <250 nm <100 nm 
Appearance Turbid Optically clear Optically clear 
Hydrophilic-lipophilic balance (HLB) value <12 >12 >12 
Classification as per LFCS Type II Type IIIB Type IIIB 
Concentration of oil 40-80% >20% >20% 
Concentration of surfactant 30-40% 40-80% 40-80% 
 
Colin Pouton categorically classified lipid-based formulations due to 
their diversity. The lipid formulation classification system (LFCS) 
categorized into four categories (table 2) [13]. All categories include 
formulations with isotropic systems, usually of mixtures but also 
consist of single excipient e. g. oil. Type I lipid-based drug delivery 
system (LBDDS) include only triglyceride oil or with certain mixtures 
with its glycerides. Formulations belonging to this category potentially 
do not self-disperse, it requires bile salts, lipolysis products and also 
phospholipids to lower interfacial tension post administration [14]. 
Other categories, unlike the type I requires only a gentle agitation that 
spontaneously yields a fine emulsion. Such formulations additionally 
include surfactants along with oil components. Based on the nature of 
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surfactants employed, LFCS type II category differs from type IIIA. 
Where the type II system includes one or more lipophilic surfactant, 
and type IIIA mostly consist more hydrophilic. The latter comprises of 
oil mixtures, hydrophilic surfactant, and co-solvents. Moreover, type 
IIIB systems comparatively consist lesser concentration of oil and 
include higher concentrations of hydrophilic surfactants with more co-
solvents. Finally pertaining to category IV consists of no amount of oil, 
typically include surfactants and co-solvents only. 
  
Table 2: the Lipid-based classification system 
Excipients The content of formulation (%, w/w) 
Type I Type II Type IIIA Type IIIB Type IV 
Oils: triglycerides mixed mono and diglycerides 100 40-80 40-80 <20 - 
Surfactants (HLB<12) - 20-60 - - 0-20 
Surfactants (HLB>12) - - 20-40 20-50 30-80 
Hydrophilic co-solvents (e. g. PEG etc) - - 0-40 20-50 0-50 
 
The efficiency of the LBDDS builds in the right from the selection of 
suitable vehicle composition, and coherent design for the significant 
drug candidate. Basically, for effective enhancement of oral absorption, 
the system needs to improve the rate and extent of dissolution and 
potentially should maintain the drug in the solubilized form in the GIT. 
The potential advantages extended by lipid-based formulation system 
are compromised in case of precipitation of drug occurs from the 
system. The current article emphasizes significant aspects of lipid-
based formulation and their characterization.  
Advantages of smedds 
a) Storage: Compared to other emulsions SMEDDS are potentially 
better for enabling solubility of lipophilic drugs. On storage 
creaming over time is a concern for macroemulsions, unlike 
macroemulsions SMEDDS are thermodynamically stable facilitating 
easy storage [15].  
b) Stability: As water not being a significant component in 
formulation systems pertaining to SMEDDS, in contrast to other 
emulsions possess enhanced chemical and physical stability on long-
term storage [16].  
c) Compliance and palatability: Majority of SMEDDS are effectively 
formulated into capsules or tablets dosage forms, enables effortless 
administration moreover occupies lesser volume thereby resolving 
palatability concerns and enhancing patient compliance [17].  
d) Food effects: Fate of absorption is not impeded by the presence of 
food, rather lipophilic contents aid in the absorption of the drug 
from the formulation systems [18].  
e) Quick onset of action: SMEDDS prominently expedite spontaneous 
and rapid oral absorption of the active, significantly result in the 
quick onset of action [19].  
f) Simple manufacturing and scale-up: Comparatively employing 
simpler and economical manufacturing facilities it’s easier to 
manufacture SMEDDS at large scale [20].  
Limitations of smedds 
SMEDDS formulations significantly possess various advantages, 
albeit inevitable limitations associated with the formulation system;  
a) Drug precipitation: during dilution in gastrointestinal fluids, 
active undergo precipitation from the formulation system. It is 
necessary for the formulation system to maintain the drug in the 
solubilized state in GIT effectively, precipitation of active yields 
negative effects and compromises the advantages extended by the 
lipid-based formulation system.  
b) The dilution effect of lipophobic solvents increases precipitation 
propensity of the drug on dilution. Thus, consequentially requires 
incorporation of polymers to alleviate drug precipitation in vivo [21].  
c) Encapsulation in gelatin capsules: Certain demerits allied with 
gelatin capsules, volatile co-solvents incorporated in the formula 
tend to migrate to shells consequentially lipophilic drugs are 
precipitated [22]. 
d) Storage: liquid SMEDDS show difficulty in storage and handling 
besides stability concerns.  
e) Correlation between lymphatic transport and lipophilicity in 
addition to triglyceride solubility needs to be perceived with more 
precise predictive model [23].  
f) An absence of significant predictive in vitro models for 
characterising formulation systems [24].  
g) Due to the presence of unsaturated fatty acids, lipid excipients are 
susceptible to oxidation; explicit process control is required to 
restrict polymorphic alterations of excipient matrix [25].  
Drug absorption 
Lipid-based formulation systems are derived with a blend of three 
major excipients, which include oil, surfactant, and co-surfactant. 
These formulations characteristically enhance with rapid dissolution 
thus improve drug absorption from GIT, enabling the formation of 
solubilised phases by altering particle size to almost molecular state, 
giving rise to solid-state solution in the formulation system, altering 
drug uptake, efflux and deposition besides modifying transportation 
associated with enterocytes and also enriching drug transport 
through intestinal lymphatic system to systemic circulation [26-28].  
Lymphatic system 
Lymphatic system plays a significant role with its considerable network 
throughout the body in transporting the drug to the systemic circulation. 
Lymphatic transport of drug surpasses the first-pass metabolism and 
also aids in targeting certain disease conditions associated with the 
lymphatics, like lymphomas. The promising mechanism includes (I) 
facilitating transcellular absorption as a result of improved membrane 
fluidity, (II) opening of tight junctions enabling paracellular transport, 
(III) inhibition of P-glycoprotein (p-gp) and CYP450 yielding to enhanced 
intracellular concentration and also increased surfactants residence 
time, (IV) stimulating lipoprotein/chylomicron production [29]. 
Digestion and solubilization 
The equilibrium among the solubility of the drug in the aqueous 
phase of the GIT and permeation over the lipophilic membrane 
govern its rate and extent of absorption [30]. Gastric lipase 
instigates the digestion of triglycerides to post oral ingestion of the 
lipid-based formulations. Crude emulsion is formed from the 
mechanical mixing of the stomach. Triglyceride is further breaking 
down to di-and monoglyceride in the small intestine and fatty acid 
by pancreatic lipase along with its co-factor co-lipase203, acting 
predominantly at sn-1 and sn-3 positions of triglyceride to yield 2-
monoglyceride and free fatty acid [31].  
The sn-2 position of phospholipids is hydrolysed to 
lysophosphatidylcholine and fatty acids by pancreatic phospholipase A2 
and exogenous lipids present in small intestine trigger secretion of 
endogenous lipids from the gallbladder, comprising phospholipids, bile 
salts, and cholesterol [32]. Formerly formed monoglycerides, 
lysophospholipids, and fatty acids are consequently combined into a 
series of colloidal structures along with micelles and vesicles (uni/multi-
lamellar) in existence of bile salts. These formed metabolites significantly 
enhance solubilization and absorption potential of the small intestine for 
digested lipids and subsequent drug. 
Effects of lipid-based excipients 
Oral dosage forms significant in vivo performance is pronounced by 
the solubility of the lipophilic drug. Since drug mostly remains in the 
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solubilized state in LBDDS, as a result, the dissolution step is 
circumvented. This gives the vital advantage for delivery of 
lipophilic drugs, but this phenomenon is inadequate if the 
solubilized state is lost upon aqueous dilution and dispersion. If the 
active precipitates, it is believed that the rate of re-dissolution is low 
compared to intestinal transit time. Thus, such precipitation results 
in poor drug absorption. However always precipitation doesn’t 
initiate inconsistent drug absorption. In certain occurrences in 
which precipitate has time for re-dissolution. Drug solubility and 
also the amount of drug precipitate in comparison with dose 
influence the kinetics [33, 34]. It is observed precipitation in the 
amorphous state is positively less critical for re-dissolution 
compared to the crystalline state. 
Preferably, LBDDS efficiently delivers a drug in solubilised form and 
sustain ample solubilisation throughout the gastrointestinal transit. 
Lipid-based excipients proficiently enhance drug solubility and can 
promote supersaturation that is adequate for drug absorption. 
Besides the effects of solubility and drug release, the formulation 
system further promotes by additional mechanisms that potentially 
influence oral bioavailability. Most of the lipid-based excipients like 
fatty acids, glycerides and surfactants are inherently enhance 
permeability. This might be resultant of altered membrane fluidity 
or tight junctions. Alternatively, excipients enhance permeability 
when they effectively interact with efflux transporters. Most familiar 
efflux transporter in the human intestine e. g. p-gp. Once the efflux 
pump is inhibited by lipid excipients substrates are believed to 
observe enhanced permeation. Most of the polysorbates, 
polyethylene glycols, medium-chain glycerides co-polymers of 
pluronics exhibit inhibiting properties on efflux transporters. 
Surfactants possessing amphiphilic structure precisely inhibit p-gp. 
Furthermore, amphiphilic surfactants influence other efflux 
transporters like breast cancer resistance protein (BCRP) [35]. 
Mostly lipid-based excipient modifies drug absorption by various 
mechanisms. Majority of the surfactants that affect efflux transporters 
usually affect drug solubilisation. Excipients certain times are capable 
of influencing cytochrome P450 metabolism of drug besides p-gp 
transporter in the intestine. In conclusion to certain aforesaid 
mechanisms, surfactants show additional simulate lipoproteins 
secretion in intestine e. g. chylomicrons. Drugs transported through 
the lymphatic pathway are benefited with the altered chylomicron 
synthesis. All these contemplations deliberately exhibit that excipients 
in a formulation system are essentially several functions. As several 
mechanisms are associated with formulation system, it becomes 
challenging to predict and understand the biopharmaceutical effects of 
the formulation system. Predominantly formulation systems yield 
beneficial effects on bioavailability of lipophilic drugs. In the case of 
soluble molecules desire a protective outcome from enzymatic or 
chemical degradation in the formulation system. 
Mechanism of self-emulsification  
Reiss recommended that self-emulsification occurs when an entropy 
change intended for dispersion is superior over the energy essential 
to upsurge the surface area of the dispersion [36]. In a typical 
emulsion formation, the free energy is a direct function of the energy 
essential to yield new surface amid two phases and is understood by 
the given equation. 
ΔG = ∑Ni  π ri2σ 
Where ΔG denotes free energy related to the process (overlooking 
the free energy of mixing), N denotes the number of droplets, r is the 
radius of the formed droplet and σ represents interfacial energy 
with time. 
In order to lower the interfacial area, the two phases of the emulsion 
favour separation with the time, giving rise to the free energy of the 
systems. Stabilization of emulsion employing typical emulsifying 
agents posts aqueous dilution by producing a monolayer around the 
emulsion droplets, thereby lowering the interfacial energy further 
preventing coalescence by forming a barrier. Unlike typical, self-
emulsifying systems potentially emulsify spontaneously since free 
energy essential to produce the emulsion is very low beside positive 
or negative [37].  
To emulsify it is essential for the interfacial structure to remain 
immune to surface shearing since emulsification necessitates slight 
input energy, presume destabilization by shrinking local interfacial 
zones. Through significant water penetration into several liquid 
crystals and other structural components present on the droplet’s 
surface facilitate better emulsification [38, 39]. 
By the incorporation of a binary blend (oil/surfactant) to water 
yields an interface between oil and aqueous phases. As a 
consequence of aqueous penetration through the interface water is 
solubilised within oil phase. This process of solubilisation takes place 
until the limit is reached near to the interphase [40]. Furthermore, the 
dispersed liquid crystal phase is formed as an outcome of aqueous 
penetration. Ultimately resulting in liquid crystal in the vicinity with 
the interface, the surfactant concentration in the binary mixture 
governs the true amount. Thereby with moderate agitation water 
expeditiously penetrate into aqueous cores and promote interface 
disruption including droplet formation. Due to development of liquid 
crystal interface neighboring the oil droplets, stability in terms of 
coalescence is imparted to the formulation system.  
Rationale for selection of smedds components 
Characteristically SMEDDS formulation includes drug, oil, surfactant, 
and co-surfactant;  
Drug 
For the development of SMEDDS formulation, the lipophilicity along 
with the dose of the active should be thoroughly scrutinized. 
Preferably, the drug should possess low dose; log p ≥ 2 moreover 
should not be susceptible to the first-pass metabolism. The drug 
inherently should exhibit significant solubility in pharmaceutically 
acknowledged lipids, surfactants and co-solvents [41]. 
Oils 
Medium chain triglycerides possessing carbon atoms ranging from 6 
and 12 are fundamentally transported by the portal blood to the 
systemic circulation. However long-chain triglycerides possessing 
carbon atoms higher than 12 are transported through intestinal 
lymphatics. Since medium chain triglycerides prominently have high 
solvent capacity moreover not susceptible to oxidation, they are 
potentially employed in lipid-based formulation systems [42, 43].  
Surfactants 
Surfactants contribute the interfacial film besides the interfacial 
tension being greatly reduced to a low value which enables the 
dispersion process. HLB value and concentration of surfactant are 
significant in the selection of surfactant. For an efficient 
performance, the emulsifier employed in the system should possess 
HLB value higher than 12, which promote the formation of small 
o/w droplets with expeditious dispersion in aqueous media. 
Basically, non-ionic surfactant with greater HLB value is preferred 
for the formulation system as they are less toxic than ionic 
surfactants [44].  
Co-surfactants 
Flexibility to the interfacial layer is imparted by co-surfactants 
where the interfacial tension is greatly reduced to an almost 
negative value. The flexibility induces various curvatures essential to 
form micro emulsion across a wide range. As a co-surfactant mostly, 
medium chain length alcohols are employed. 
Role of excipient selection on bioavailability  
A predominantly broad range of excipients are available for 
formulating lipophilic drugs in lipid formulations. Conventionally lipid-
based systems include excipients subsequently: 1) lipids: natural or 
synthetic lipids; 2) surfactants: hydrophilic or hydrophobic non-ionic 
surfactants; 3) hydrophilic solvents: to enhance dispersion and for 
better solvent capacity; 4) co-solvents: significantly lower viscosity of 
the system and to enable dispersion. From formulation viewpoint, the 
excipient choice will influence dispersion properties, drug load, drug 
solubilization and significantly stability. Moreover, pharmacokinetic 
characteristics of excipients are also considered which may 
significantly affect the bioavailability.  
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The fundamental role of lipids is to solubilise drug and further 
sustain it in the solubilised state during the GI-tract transit. In case 
of drug precipitation as an outcome of lipid digestion, the drug must 
be resolubilized in intestinal fluids for being absorbed. This is 
essential specifically for the biopharmaceutical classification system 
(BCS) class II and IV [45]. For formulating lipid-based systems, 
diverse lipid excipients are existing like short, medium and long-
chain triglycerides. Basically, medium chained triglycerides are 
digested at a faster rate compared to long chained triglycerides and 
also former is digested completely. Furthermore because of the high 
solvent capacity drug to a greater extent is kept in a solubilised state 
in medium chained triglycerides. Whereas due to poor solvent 
capacity short chain triglycerides yields extensive precipitation of 
drug. Moreover, apart from the aforementioned lipid digestion 
aspects, considerably lipid influence the absorption profiles of the 
drug. For instance, portal vein absorption via liver is predominant in 
medium chain triglycerides and lymphatic absorption is bypassing 
the first-pass metabolism in case of long-chain triglycerides.  
Surfactants 
Extremely studied excipients in the class of non-ionic are commonly 
include cremophor EL and cremophor RH40. Albeit cremophor EL 
and cremophor RH40 belong to the same family compared to 
cremophor RH40, cremophor EL possess a lower degree of 
ethoxylation besides being unsaturated. In vivo digestion aspects 
should be scrutinized for their inclusion in the formulation. 
Concerning to the surfactants cremophor EL is more vulnerable to 
digestion when compared to cremophor RH40 [46]. The 
explanations for varied digestions are still unclear; however it has 
been attributed to variances with respect to reactivities of saturated 
castor oil glyceride backbone associated with cremophor RH40 
yields diverse reaction products compared to cremophor EL. 
Cremophor RH40 being less prone digestion significantly optimum 
for maintaining the drug in the dissolved state for an extended 
period when compared to cremophor EL [47]. Although as 
aforementioned concepts are considerable under in vivo conditions, 
the comparative affinity of lipases towards excipients will influence 
the extent of digestion and drug solubilization, signifying the 
importance formulation optimization. Additionally, low lipid 
concentrations increase the susceptibility of drug precipitation as a 
result of dilution which ultimately fails to keep the drug in the 
dissolved state. This clearly implies the inevitability to optimize the 
ratio of lipid to surfactant for improved bioavailability. Besides the 
high concentration of surfactants results in micelle formation which 
may hamper the absorption process as it increases the molecular 
weight of the entire complex. And also, prolonged use of surfactants 
is not advisable as they potentially disrupt cell membrane, toxicity 
and adverse effects [48].  
Hydrophilic solvents 
LFCS type III formulations require minor quantities of hydrophilic 
solvents like triethyl citrate, propylene glycol and polyethylene 
glycol 400 (PEG-400) are employed to facilitate emulsification 
through dispersion and stranding [49]. Apart from excipient 
toxicities handful of hydrophilic solvents possess essential 
pharmacokinetic characteristics. PEG-400 belonging to this category, 
when consumed in larger quantities affect the gastric motility and 
thereby affect drug absorption. As an outcome of poor absorption 
triggers PEG-400 induced osmotic activity on subsequent water 
retention results stimulating intestinal motility. For many drug 
molecules, small intestine predominantly facilitates major 
absorption due to declined transit time will reduce time offered for 
absorption of poorly soluble and slowly dissolving molecules. 
Nevertheless, PEG-400 at lower concentrations prominently 
enhance the absorption of certain drug molecules like ranitidine, due 
to modified intestinal permeability [50, 51]. Albeit only small 
quantities of hydrophilic solvents are employed in lipid-based 
systems, aforementioned pharmacokinetic impact should be 
considered while excipient selection.  
Cosolvents 
Basically, minimal concentrations of cosolvents like ethanol are used 
to lower viscosity besides assist in the dispersion process. At such 
low concentrations, the cosolvents are pharmacokinetically 
insignificant.  
Development of formulation 
Excipient selection for scrutinizing drug solubility 
To begin with the formulation development of lipophilic molecules 
comprehensive pharmaceutical profiling is performed. Stability and 
solubility tests should be accompanied beside biopharmaceutical 
assessment. Initial impression with drug absorption barrier is 
learned by considering the BCS class, the maximum absorbable dose 
[52-54]. With recent advancements like physiologically based 
pharmacokinetic modelling (PBPK) enable drug evaluations simpler 
[55-58]. Due to uncertain input parameters, such models are 
inadequate predictability at initial stages of the development. 
Nevertheless, PBPK modelling appreciably predict the sensitivity of 
drug absorption considering diverse factors. Specifically, dose 
fraction absorbed is significant in view of formulation parameters. In 
such instance’s formulation can be developed deliberately using 
parameter sensitivity analysis [59]. Such strategies are considered in 
SMEDDS or SEDDS. 
The formulation system should suitably balance the dose with drug 
solubility in oils. Technically preformulation data initially comprises 
drug solubility in medium and long chain triglycerides. The obtained 
solubility measures describe how accurately the desired dose 
strength is achieved. Certainly, in an optimized blend like SMEDDS 
drug solubility is extremely enhanced but there are certain demerits 
associated with the increase in solubility. Few drugs are poorly water 
solubility as a result of their lipophilicity. Such molecules possess 
higher value about 2-4 of the partition coefficient (logP), are usually 
suitable candidates for lipid-based systems. For other molecules, the 
limitation of aqueous solubility instigates from high crystal energy. 
The solubility impediment as an outcome of solid-state properties is 
most prominent with molecules possessing moderate to low 
lipophilicity [60]. For aforesaid compounds, it is mostly tough in 
identifying oil vehicles having an adequate solvent capacity. Therefore, 
such molecules should be avoided for lipid-based systems and looked 
for alternate formulation systems like solid dispersions etc. 
  
 
Fig. 1: Structured approach for explicating ideal excipients additionally development of a lipid-based system [63] 
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Table 3: Major solubilising excipients employed in commercially available lipid-based systems 
Water-soluble excipients Triglycerides Surfactants References 
Bees wax Long-chain triglycerides:  Polysorbate 20 (tween 20) [64] 
Oleic acid Hydrogenated soyabean oil Polysorbate 80 (tween 80) [64] 
Soy fatty acids Hydrogenated vegetable oil Sorbitan monolaurate (span 20) [64] 
D-α-Tocopherol (vitamin A) Corn oil, olive oil,  D-α-Tocopheryl PEG 1000 succinate (TPGS)  [64] 
Corn oil mono-di-triglycerides soyabean oil, peanut oil, Glyceryl monooleate  [64] 
Medium chain (C8/C10) mono and 
di glycerides 
Sesame oil  Polyoxyl 35 castor oil (cremophor EL) [64] 
Propylene glycol esters of fatty acids Medium-chain triglycerides:  Polyoxyl 40 hydrogenated castor oil (cremophor RH40) [64] 
 Caprylic/capric Polyoxyl 60 hydrogenated castor oil (cremophor RH60) [64] 
 Triglycerides derived from 
coconut oil or palm oil 
PEG 300 oleic glycerides (labrafil® [64]  M-1944 CS) 
  PEG 300 linoleic glycerides (labrafil® [64]  M-2125 CS) 
  PEG 400 caprylic/capric glycerides (labrasol® [64] ) 
  PEG 1500 lauric glycerides (gelucire® [64]  44/14) 
 
Once confirmed with the scrutiny of new drug candidate suitability 
for lipid-based systems, it is significant to design formulation 
development in a structured manner. (fig. 1) exhibits such an 
approach that can be employed as a formulation development 
design. 
The purpose of level-A is to achieve candidate systems for further 
screening and evaluation. This begins with the choice of prominent 
excipients and blends [61, 62]. Usually, excipients possess diverse 
functionalities in blends e. g. being an oil, surfactant, co-surfactant or 
the additive can be a solvent. (table 3) exhibits solubilizing 
excipients employed in different commercially available for lipid-
based systems. Functionality is further tough to assign, as most 
excipients like gelucire 44/14, are significantly are a complex blend 
of complex substances. Regardless of the unforeseeable character of 
any characterization, it is still considered to obtain a better 
perspective of various formulations. 
The oil is a critical component of the system. The selection is made 
from medium-to long-chain triglycerides with different degrees of 
saturation. On addition of partially or complete hydrolysed oils 
enhances dispersion behaviour and may improve the solubility of 
drug molecules. This characteristic of drug solubility must be 
addressed at an initial level as shown in (fig. 1). Mostly the 
preformulation data are accompanied by the screening of drug 
solubility in a series of several lipid-based excipients [65, 66]. 
Formulations essentially require excipients possessing high solvent 
capacity. Distinctive solvents like ethanol etc should be scrutinized 
in the primary solubility trails. Moreover, all tested excipients 
should be confirmed with the toxicological and regulatory status. 
Predominantly important for surfactants as surface actives usually 
have critical tolerability [67].  
TGPS is considered suitable for the formulation being the derivative 
of vitamin E is well endured and benefits from broad regulatory 
acceptance. But the excipient grades must be cautiously evaluated 
concerning regulatory aspects. Based on the resultant excipient 
precedencies the additive is restricted to both preclinical, and early 
clinical studies or a universal regulatory acceptance is possible to 
enable a market formulation. The usage of excipients without 
compliance with regulatory aspects must be discouraged. Certain 
times drug properties necessitate excipients that have low 
regulatory status and impartial regulatory data. In such cases, the 
formulator should emphasize the feasibility of formulation that can 
be approved for the market. 
The emphasis must balance the concentration of additives along 
with the medical indication of the compound. Particularly the high 
concentrations of surface actives must be critically evaluated in view 
of risk/benefit aspects. The concentrations of surfactants and the 
additives should be optimised for achieving the maximum drug 
solubilization. From the solubility studies, it is probable that alone 
pure oils or a minimal surfactant concentration provide insufficient 
solvent capacity for a molecule. Apart from the aforesaid possibility 
of preferring SEDDS/SMEDDS over pure oils. Further SMEDDS are 
positively compared against type I systems over biopharmaceutical 
advantages. These self-emulsifying systems are believed to be less 
reliant on lipolysis than simple oil mixtures [68, 69]. SMEDDS 
potentially lowers susceptibility to the discrepancy in exposure due 
to variable lipid digestion. 
Evaluation of phase behaviour and biological properties of 
excipients 
For an efficient lipid-based system needs a thorough knowledge of 
mixing behaviour of the components. Ternary phase diagrams are 
often employed to determine structural phase behaviour from 
subsequent emulsification and further characterizing behaviour of a 
formulation through dilution path [70, 71]. An example represented 
in (fig. 2) dilution of the formulation is characterized from line A to B 
consisting primarily of 35% surfactant and 65% oil passing over 
regions of a W/O microemulsion and a lamellar liquid crystal until 
attaining a stable bi-continuous O/W microemulsion post-dilution. 
For a given formulation it is significant to understand the structures 
arising along dilution path to guarantee stable dispersed structures 
upon dilution. Optimum ratios of low and high HLB surfactants 
potentially yield smaller droplet size over single surfactant. Such 
more complex mixtures can be evaluated using pseudo-ternary 
diagrams where a specified surfactant mixture and oil mixture 
would aid as the oil or surfactant top of the diagram; likewise, co-
solvents can be evaluated as part of the oil or surfactant mixture.  
Preferably drug solubility and dispersions are evaluated 
simultaneously. Although the presence of co-solvent may improve 
drug solubility in the formulation system, high amounts of 
hydrophilic solvents result in drug precipitation post dispersion as a 
result of diffusion of co-solvent into the bulk aqueous phase. 
Presence of adequate amount of lipid aids in the formation of 
supersaturated systems that certainly lowers precipitation for a 
suitable period [72]. With recent high-throughput screening enables 
evaluating drug solubility and dispersion properties concurrently 
that assist in determining formulations with optimal behaviour 
conforming to both factors [73].  
For the suggestion of candidate formulations further requires 
consideration of biological excipients effects. Mainly pertaining to 
drug efflux transporters and their modulation. Certain key aspects 
are discussed concerning SMEDDS formulations. 
Most of the drugs are inherently substrates of efflux transporters that 
are positioned in the apical membrane of the human intestine. P-gp is 
known to possess a broad range of substrates few e. g. are doxorubicin, 
paclitaxel, saquinavir, cyclosporin, dexamethasone, and cimetidine 
[74-79]. A more recent defined ATP-binding cassette (ABC) 
transporter is BCRP. It is learned that it excretes mitoxantrone and 
further substrates were reported as prazosin, imatinib [80-81] — 
furthermore, the ABC transporter that belongs to the group of 
multidrug resistance proteins like P-gp. Multidrug resistant-associated 
protein 2 (MRP2) also efflux for reported e. g. pravastatin, ritonavir 
certainly expressed on the apical side of enterocytes [82-84]. 
Lipid-based excipients are capable of interacting with efflux 
transporters and most significant with surface actives. Some of the 
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reported surface actives are listed in (table 4) which exhibited drug 
transport inhibition. Majority of the orally accepted surface actives 
interact with either of the efflux transporters. Though the specificity 
makes a difference. Inhibition of P-gp was evident in many cases 
while interaction with BCRP was seen only with pluronic block 
polymers and polysorbate 20. Such transport inhibition was not 
reported for polysorbate 80, but both grades 20 and 80 would 
effectively impact MRP efflux. 
  
 
Fig. 2: Exemplary ternary phase diagram of an oil-surfactant water system, based on a C12E10-oleic acid water system [85] 
 
The references mentioned in (table 4) were attained under 
diverse experimental conditions. Hence it is hard to relate these 
findings to human drug absorption. Though certain clinical 
absorption data is available results are difficult to interpret since 
several factors influence the fraction of drug absorbed. 
Differentiation of these bewildering effects, therefore, is a 
significant challenge. It is acknowledged from in vitro tests that 
P-gp inhibitors are frequently also inactivated cytochrome 
P 450
In an overview, excipients are scrutinized in regard to drug solvent 
capacity and phase behavior. If there is a rationale for suggested 
drug biological aspects along with effects of efflux transporters and 
CYP3A4 should be reviewed. After a thorough screening candidate 
system that exhibits encouraging results is proposed and further in-
vitro tests are performed. The significance of the aforementioned 
screening tests is debated matter hence it is judicious to have a 
better understanding at the level of absorption. 
(CYP)3A4 [86]. There is a large overlay of the inhibitor 
specificity of CYP3A4 and P-gp, as a result, drug efflux is not an 
isolated mechanism, but it is related to the extent of drug 
metabolism [87].  
 
Table 4: List of surfactants that inhibit efflux transporters 
Excipient Transporter 
Polyoxyl 40 hydrogenated castor oil (Cremophor RH40) P-gp 
Polyoxyl 35 castor oil (Cremophor EL) P-gp 
Capryol caproyl macrogol glycerides (Labrasol) P-gp 
Medium-chain mono-di-and tri-glycerides (Imwitor 742)  P-gp 
Lauryl macrogol-glycerides (Gelucire 44/14)  P-gp 
A mixture of diacylglycerols (Peceol) P-gp 
Phospholipids  P-gp 
Pluronic block copolymers (Pluronic P85) P-gp, MRPs, BCRP 
Polyoxyethylene sorbitan monooleate (Polysorbate 80)  P-gp, MRPs 
Polyoxyethylene sorbitan monolaurate (Polysorbate 20) P-gp, MRPs, BCRP 
D-α-Tocopheryl PEG 1000 succinate (TPGS) P-gp 
PEG 660-12-hydroxy-sterate (Solutol HS)  P-gp 
 
Characterization of lipid-based systems 
In vitro studies 
The in vitro testing should mimic the environment of the stomach 
and intestine anticipate the performance. A primary understanding 
of formulation development and its drug release can be attained 
from in vitro testing. Studying the modifications of the formulation in 
the GIT is crucial for understanding drug absorption from lipid-
based formulations. The release study from formulation system can 
foresee in vivo performance or can mainly aid as a quality control 
tool. The test technique and the medium are selected based on the 
objective. In common all tests pertain to the generation of new 
interfaces by dispersion. Droplets or colloidal structures produced 
upon dilution from which drug is released to acceptor medium [88].  
Probably the pH influences the release rate from the formulation 
system. Certain drugs exhibit pH-dependent solubility moreover 
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dispersion itself can be affected by pH. Generation of new interfaces 
is greatly influenced by proton concentration or ionic strength 
besides the zeta potential of the particles. Mostly poorly soluble 
bases are sensitive to pH. In this case, though a neutral to alkaline 
pH range is most crucial concerning low solubility. Drug 
precipitation is of more concern regarding lipid formulation, the 
kinetics and extent of drug precipitation is a measure for selecting 
one formulation over other. However, the in vivo condition should be 
precisely studied since the relevance of such invitro precipitation is 
specifically uncertain concerning drugs that are highly permeable. 
Rapid drug absorption may occur in vivo so that removal of luminal 
drug averts a crushing out. Such occurrences are not measured by a 
simple release, neither the digestion process is considered. The 
latter characteristic led to the development of a dynamic invitro 
lipolysis model.  
Testing requires a pH-stat titration system; the basic working 
principle is maintaining a persistent pH (pH must be maintained to 
avoid inhibition of the lipase) throughout a reaction which 
releases/consume hydrogen ions. Origination of any deviation is 
compensated by reagent addition. The model comprises of a 
temperature-controlled vessel (37℃P), which holds a suitable 
medium, composed of digestion buffer, phospholipid and bile salt. 
Calcium chloride may be primarily added or it can be continuously 
pumped throughout the process. Lipid-based formulation system is 
introduced into this model, and the digestion process is initiated 
further pancreatic lipase and co-lipase are added. Commencement of 
digestion results in the liberation of fatty acids, thereby a transient 
drop in pH is observed. This drop is measured by the pH electrode. 
The pH electrode is attached to a pH-stat meter controller apart 
from auto-burette. An equimolar amount of sodium hydroxide is 
added to titrate the liberated fatty acids with the auto-burette, so as 
to avoid a variation in pH of digestion medium. The degree of 
digestion can be measured by quantifying the rate of addition of 
sodium hydroxide and considering the stoichiometric relation 
between fatty acids and sodium hydroxide. Throughout the 
digestion, process samples can be withdrawn and divided into the 
poorly dispersed oil phase, highly dispersed aqueous phase and 
precipitated pellet phase obtained by centrifugation. Computing 
amount of drug in the highly dispersed aqueous phase suggests drug 
has not precipitated, from which an assumption can be made 
concerning in vivo performance. The concentration of the bile salts, 
calcium and lipase activity had an influence on the initial rate of 
hydrolysis while the consequent stages are influenced by calcium 
concentration and lipase activity [89, 90]. Dahan and Hoffman have 
presented the significance of in vitro lipolysis model for optimizing 
the oral-based formulation concerning to pre-systemic metabolism 
in the gut [91].  
In vivo studies 
Suitable in vivo studies significantly assess the influence of 
excipients pertaining bioavailability and pharmacokinetic profile of 
the drug. Subsequently, lipid-based formulations increase the 
bioavailability through improving the intestinal uptake hence a 
comprehensive understanding of the intestinal lymphatic absorption 
is required. As a reason of inadequate clinical data and variations in 
the method and animal model employed, it has become tough to 
carry studies involving the drug transport [92]. Henceforth work has 
to be carried out to establish an in vivo method and model to foresee 
lymphatic drug transport. A study in a mesenteric lymph duct-
cannulated rat model was performed to learn the mechanism for 
enhanced bioavailability for marketed formulation (Fortovase®
In lymphatic absorption, the significant step is the interaction of the 
drug with the chylomicrons in the enterocytes. To study the above-
mentioned phenomenon, an experimental rat model was used with 
blocked chylomicron flow to explicate the lymphatic transport of 
vitamin D
). The 
results revealed that the principal reason for improved bioavailability 
was due to enhanced solubilization and permeability of the drug in the 
lipid-rich pre-absorptive intestinal environment [93].  
3 was performed. When the results of mesenteric lymph 
duct-cannulated rat model were compared it exhibited that the 
association with chylomicrons guided a 75% of the vitamin D being 
absorbed through lymphatic uptake [94-96]. The influence of food 
(mostly high fatty meal) on the bioavailability of cyclosporin was 
considered by formulating the drug as Sandimmune Neoral®
In vitro-in vivo correlation (IVIVC) 
 (Lipid-
based system), and simple emulsion encapsulated in soft gelatin 
capsules and was subjected to healthy human volunteers. It was 
clear from the results that the lipid-based system is less affected by 
food when compared to the substantial effect of food from the 
simple emulsion. This significantly facilitated a broad range to the 
lipid-based system with respect to their dietary supplement.  
Amidon et al. pivotal article describes the use of in vitro-in vivo 
correlation for various BCS classes. BCS class I drugs are the most 
suitable candidates while the class IV drugs are considered to be poor 
candidates for IVIVC due to their solubility and permeability 
characteristics. Whereas for class III IVIVC applicability is restricted 
due to their poor permeability. The solubility properties for class II 
compounds can critically improve with lipid-formulation thus 
achieving comparable to class I compounds. The rapid release profiles 
attained will allow the time required to be prominently less than 
gastric emptying time, thus improving the possibility of accomplishing 
robust IVIVC correlation [97]. Lipid-formulations belonging to type II 
and III rapidly disperse in the biological fluids thereby complete 
solubilization in biological fluids is achieved in lesser time which 
increases the potential for accomplishing IVIVC for class II compounds. 
A comprehensive IVIVC will guide to develop potential and 
commercially viable lipid-system. A quick drug development with 
better product attribute could be accomplished with a potential model 
that correlates the in vitro and in vivo data. Computing the solubility, 
dissolution, intestinal membrane methods (cell culture and isolated 
animal tissue models) along with lipolysis of the lipid excipient are 
several in vitro techniques and are prominently employed to evaluate 
lipid-based formulations [98]. Aforesaid techniques suggest 
information limiting to specific aspects of the formulation. However, it 
is important to understand the in vivo interaction and performance of 
these systems.  
Chylomicrons are produced and secreted by Caco-2 cells on 
exposure to lipids, similar to in vivo enterocytes. The rat is a 
dependable model for preliminary screening and determining a 
formulation prototype. But due to diverse anatomical and 
physiological aspects of rat, like the absence of gallbladder and 
unalike expression and pattern levels for intestinal enzymes makes a 
correlation to human beings difficult. Several lipid-systems have 
been assessed employing dog model, however, poor correlation was 
observed amid dog and human due to variations in GIT physiology, 
like gastric pH besides enzymatic profile of enterocytes [99]. The pig 
deliberately believed to be a most suitable non-primate animal 
model for achieving close relation amongst the GIT anatomy and 
physiology [100]. This model allows the oral administration of the 
complete human dose, also food effects can be studies. The influence 
of intestinal absorption and first-pass metabolism of drugs can be 
studied with the aid of a pig model [101]. Therefore, to establish 
consistent in vitro-in vivo correlation in lipid-systems, ideal and most 
appropriate in vitro and in vivo models is of prime importance.  
Final dosage form besides comparison of several technological 
strategies  
Several prospects are available for developing the final dosage form 
of the lipid-based system for marketing. Modifications of the 
compositions can be considered only if the dosage form is 
categorised early enough. Characteristics regarding the filling 
process besides the compatibility of fill mass with capsule shells etc 
must be considered. Mostly process includes rotary die filling of soft 
gelatin capsules though other techniques have immensely gained 
importance over recent years.  
Industries are currently keen in using alternative materials apart 
from gelatin for capsule shells. These days technical advancements 
enable to liquid-fill hard gelatin capsules on different batch scales. 
Sealing is achieved either by banding or by using liquid 
encapsulation by micro spray (LEMS), comparably it is less 
complicated to produce liquid-fill hard gelatin capsules than soft 
capsule technology [102]. Additionally, former resist much high 
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filling temperatures (~70℃) compared to soft gelatin (~40℃). 
Excluding these benefits of hard gelatin, other aspects suggest the 
benefits of soft gelatin technology. Soft gelatin capsules have an edge 
for shell compatibility for hygroscopic excipients. Furthermore, an 
insufficient filling of the two-piece hard capsules can encourage 
leaking of fill mass. Most prominently more fill mass, and 
consequently higher doses can be subsumed into soft gelatin capsules 
since unlike hard gelatin capsules which possess headspace these are 
completely filled.  To infer soft and hard capsules equally have merits 
and demerits so that no technology is basically considered superior 
over other. For specific projects necessity, suitable technology is 
selected. Right so for solid lipid-based systems. Various technologies 
exist for this formulation that suggests an alternative to the typical 
incorporation of a fill mass into a capsule. 
Typically, lipid-based systems can be transformed into a solid 
dosage form is achieved by adsorbing onto a carrier [103-105]. 
Nanoparticulate excipients are mostly preferred due to their high 
surface area as solid carriers. Adsorption onto the carriers is 
achieved certainly in a high shear mixer. As an alternative technique 
melt granulation is used with simple mixtures of waxy excipients 
with a traditional granulation process. This technique has an edge of 
producing high yielding drug load as the drug exists in coarse 
crystalline form. Adsorbates possess biopharmaceutical benefits of 
the larger surface area beside amorphous physical state. Solid 
dispersions by means of lipid-based excipients are highly 
commendable, owing to their high dose along with rapid release 
profile. But similar to other systems the solid dispersion must be 
evaluated for in-vitro to assess the potential of the drug to remain in 
solubilized form post-dilution. Furthermore, lipid excipients exhibit 
prominent mechanisms to improve bioavailability. Hence it is 
significant for the final dosage form to comprise high lipid content. 
High lipid load can simply attain by filling hard/soft gelatin capsules. 
These typically have potential scale-up properties unlike melt 
granulation or adsorbates. Albeit the latter techniques can deliver 
tablets and have benefits over capsules in terms of cost control 
[106]. All these signify that selection of dosage form must possess 
ideal biopharmaceutical aspects along with technical considerations 
besides economical. (table 5) enlists Food and Drug Administration 
(FDA) approved drugs employing lipid systems. 
  
Table 5: FDA approved drugs employing lipid systems 
Molecule/Trade name New drug application (NDA) year LFCS Drug category References 
Ergocalciferol (Drisdol® 1941 ) I Vitamin D analog [107] 
Calcitriol (Rocaltrol® 1978 ) I Vitamin D analog [107] 
Valproic acid (Depakene® 1978 ) I Anti-epileptic [107] 
Isotretinoin (Accutane® 1982 )–discontinued I Retinoid [107] 
Cyclosporin A (Sandimmune® 1983 ) II Calcineurin inhibitor [107] 
Dronabinol (Marinol® 1985 ) I Cannabinoid [107] 
Clofazimine (Lamprene® 1986 )–discontinued I Anti-leprosy [107] 
Cyclosporin A (Sandimmune® 1990 ) II Calcineurin inhibitor [107] 
Ranitidine (Zantac® 1994 )–discontinued  H2-recptor antagonist [107] 
Cyclosporin A (Neoral® 1995 ) IIA/IIIB Calcineurin inhibitor [107] 
Cyclosporin A (Neoral® 1995 ) IIA/IIIB Calcineurin inhibitor [107] 
Tretinoin (Vesanoid® 1995 )–discontinued I Retinoid [107] 
Ritonavir (Norvir® 1996 ) IIIA Protease inhibitor [107] 
Saquinavir (Fortovase® 1997 )–discontinued  Protease inhibitor [107] 
Progesterone (Prometrium® 1998 ) I (susp) Hormone [107] 
Amprenavir (Agenerase® 1999 )–
discontinued 
IV Protease inhibitor [107] 
Bexarotene (Targretin® 1999 ) IV Retinoid [107] 
Doxecalciferol (Hectorol® 1999 ) I Vitamin D analog [107] 
Sirolimus (Rapamune® 1999 ) III mTOR kinase inhibitor [107] 
Cyclosporin A (Gengraf® 2000 ) IV Calcineurin inhibitor [107] 
Cyclosporin A (Gengraf® 2000 ) IV Calcineurin inhibitor [107] 
Ritonavir/lopinavir (Kaletra® 2000 )–
Discontinued 
III Protease inhibitor [107] 
Dutasteride (Avodart® 2001 ) I 5 alpha-reductase inhibitor [107] 
Isotretinoin (Claravis® 2003 (ANDA) )  Retinoid [107] 
Omega-3-acid ethyl esters (Lovaza® 2004 ) I Fish oil for lipid digestion [107] 
Tipranavir (Aptivus® 2005 ) IIIA Protease inhibitor [107] 
Tipranavir (Aptivus® 2005 ) IV Protease inhibitor [107] 
Paricalcitol (Zemplar® 2005 ) I Vitamin D analog [107] 
Lubiprostone (Amitiza® 2006 ) I Chloride channel activator [107] 
Fenofibrate (Lipofen® 2006 ) III Peroxisome proliferator 
activated receptor α (PPARα) 
activator 
[107] 
Topotecan HCl (Hycamtin® 2007 ) I Topoisomerase inhibitor [107] 
Loratadine (Claritin® 2008 )  Antihistamine [107] 
Isotretinoin (Absorica® 2012 )  Retinoid [107] 
Enzalutamide (Xtandi® 2012 ) I Androgen receptor inhibitor [107] 
Nintedanib (Ofev® 2014 ) II Tyrosine kinase inhibitor [107] 
Calcifediol (Rayaldee™) 2016 II/III Vitamin D analog [107] 
 
CONCLUSION 
A significant opportunity along with a potential challenge is 
anticipated from most insoluble drug molecules approved by FDA, 
besides those in the development stage. At present lipid-systems are 
in emphasis for developing formulation of poorly water-soluble 
drugs. Self-emulsifying systems deliver an appropriate approach to 
deal with a biopharmaceutical challenging drug. To understand a 
clear rationale for the formulation development, precise 
biopharmaceutical aspects should be considered. Later a thorough 
sequence of screening tests is performed for the selection of 
formulation excipients. The crucial intent is to retain the drug in 
solubilized form since drug precipitation confines the oral 
bioavailability. The portion of this preliminary focus on drug 
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absorption is the consideration of excipient effects on presystemic 
clearance or inhibition of efflux transporters. Prior to the final 
composition certain technical aspects are considered pertaining to 
product manufacture. The excipient concentration and their grades 
can only be altered within the parameters of solubility and phase 
behaviour. With specific rationale, it seems worth capitalizing 
development resources in lipid-based systems. Given the major 
biopharmaceutical potential it is believed that more new actives will 
be formulated as lipid-systems, also will benefit from this fascinating 
formulation approach. 
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